Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / October 23, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Aspen Technology, Inc. (NASDAQ:AZPN) concerning potential violations of the federal securities laws and/or breaches of fiduciary dut...
NEW YORK, NY / ACCESSWIRE / October 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Umpqua Holdings Corporation (NASDAQ:UMPQ) concerning potential violations of the federal securities laws and/or breaches of fiduciar...
NEW YORK, NY / ACCESSWIRE / October 15, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Columbia Banking System, Inc. (NASDAQ:COLB) concerning potential violations of the federal securities laws and/or breaches of fiduci...
Fixed income investor Bill Gross reiterates his view on the "garbage" bond market, saying 10-year U.S. Treasury yields are likely to rise to 2% over the next year, according to his October Investment Outlook. The 10-year UST yield appears to have formed resistance at around 1.60% this week, n...
An understaffed U.S. Federal Trade Commission is taking a longer and harder look at deals even as merger activity surges. 369 deals fell under review requirements in August, twice as many as the same month last year. A higher price and bigger break fees can compensate somewhat for...
NEW YORK, NY / ACCESSWIRE / October 8, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Acceleron Pharma Inc. (NASDAQ:XLRN) concerning potential violations of the federal securities laws and/or breaches of fiduciary dutie...
First, there were rumors that Merck (NYSE: MRK) might acquire Acceleron Pharma (NASDAQ: XLRN) . Then those rumors were confirmed, with the big pharma company announcing plans to buy Acceleron for $11.5 billion. In this Motley Fool Live video recorded on Sept. 29, 2021 ...
NEW YORK, NY / ACCESSWIRE / October 6, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Acceleron Pharma Inc. (NASDAQ:XLRN) concerning potential violations of the federal securities laws and/or breaches of fiduciary dutie...
With patent protection for blockbuster cancer therapy Keytruda set to expire in 2028, Merck (NYSE:MRK) is on the deal hunt, The Financial Times reports citing Mirati Therapeutics (NASDAQ:MRTX), Arcturus Therapeutics (NASDAQ:ARCT), and Biogen (NASDAQ:BIIB) as potential candidates. Ac...
Merck acquires Acceleron for $180 per share in cash. Amicus Therapeutics to launch a genetic medicine company, Caritas Therapeutics through a business combination agreement with ARYA Sciences Acquisition Corp IV. Five9 and Zoom Video Communications mutually terminate their merger ...
News, Short Squeeze, Breakout and More Instantly...
Acceleron Pharma Inc. Company Name:
XLRN Stock Symbol:
NASDAQ Market:
Acceleron Pharma Inc. Website:
Believes Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process Remains Confident in Company’s Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Stands Ready to Hel...
In September, Merck (NYSE: MRK) announced plans to acquire Acceleron Pharma (NASDAQ: XLRN) for $11.5 billion. However, the big drugmaker recently revealed that it withdrew a key regulatory filing document related to the transaction. In this Motley Fool Live video ...